Compare PCRX & PCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCRX | PCN |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 999.0M | 872.0M |
| IPO Year | 2010 | 2001 |
| Metric | PCRX | PCN |
|---|---|---|
| Price | $25.41 | $11.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $30.25 | N/A |
| AVG Volume (30 Days) | ★ 642.3K | 323.3K |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.44 | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $541,533,000.00 | N/A |
| Revenue This Year | $6.78 | N/A |
| Revenue Next Year | $8.54 | N/A |
| P/E Ratio | $131.68 | ★ N/A |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $11.40 |
| 52 Week High | $27.66 | $13.49 |
| Indicator | PCRX | PCN |
|---|---|---|
| Relative Strength Index (RSI) | 44.73 | 60.57 |
| Support Level | $24.61 | $11.47 |
| Resistance Level | $26.94 | $12.09 |
| Average True Range (ATR) | 1.00 | 0.11 |
| MACD | -0.25 | 0.03 |
| Stochastic Oscillator | 18.84 | 100.00 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
PIMCO Corporate & Income Strategy Fund is a closed-end management investment company. Its objective is to seek high current income with capital appreciation as a secondary objective. It invests in corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, short-term instruments, and others.